Regulatory dendritic cell therapy in organ transplantation

Curr Opin Organ Transplant. 2023 Nov 23. doi: 10.1097/MOT.0000000000001127. Online ahead of print.ABSTRACTPURPOSE OF REVIEW: Regulatory dendritic cells (DCregs; also 'tolerogenic DCs'), innate immune cells that regulate the alloimmune response, are a novel cellular therapy for organ transplantation. Preliminary results from early-phase clinical trials in live donor kidney and liver transplantation are promising. This follows many years of research elucidating mechanisms of action and utility of DCregs. Herein, we review early-phase clinical trial observations and recent advances in the production, modification, and future-trajectory of DCreg in organ transplantation.RECENT FINDINGS: Preclinical work has demonstrated the ability of adoptively transferred DCreg to abrogate ischemia-reperfusion injury and promote long-term allograft survival. Good Manufacturing Practice-grade DCregs have been generated in adequate numbers for early-phase trials of autologous DCregs in kidney transplantation and donor-derived DCreg in liver transplantation. These trials have demonstrated feasibility and safety, with preliminary evidence of an influence on host immune reactivity. In both kidney and liver transplantation, reduced effector CD8+ T-cells have been noted, together with other changes that may be conducive to reduced dependence on immunosuppressive therapy.SUMMARY: Substantial progress has been made in bringing DCreg to clinical testing in organ transplantation. Additional clinical and m...
Source: Current Opinion in Organ Transplantation - Category: Transplant Surgery Authors: Source Type: research